MedImmune LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1987-01-01

Employees: 5K

Market Cap: -

Website: http://medimmune.com

Clinical Trials

A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Other: Placebo
Drug: 100mg Mavrilimumab
Drug: 150mg mavrilimumab

First Posted Date: 2014-08-11

Last Posted Date: 2015-01-09

Lead Sponsor: MedImmune LLC

Target Recruit Count: 39

Registration Number: NCT02213315

Locations: 🇬🇧
Research Site, London, United Kingdom

A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

Phase 1

Terminated

Conditions: Advanced Solid Tumors
Aggressive B-cell Lymphomas

Interventions: Biological: MEDI6469 Monotherapy
Biological: MEDI6469 Plus Tremelimumab
Biological: MEDI6469 plus Rituximab
Biological: MEDI6469 Plus Durvalumab

First Posted Date: 2014-07-31

Last Posted Date: 2017-06-28

Lead Sponsor: MedImmune LLC

Target Recruit Count: 48

Registration Number: NCT02205333

Locations: 🇺🇸
Research Site, Houston, Texas, United States

N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Phase 2

Completed

Conditions: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

Interventions: Drug: Inebilizumab
Other: Placebo

First Posted Date: 2014-07-25

Last Posted Date: 2021-12-03

Lead Sponsor: MedImmune LLC

Target Recruit Count: 231

Registration Number: NCT02200770

Locations: 🇹🇷
Research Site, Samsun, Turkey

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Biological: MEDI4920 3 mg
Biological: MEDI4920 10 mg
Biological: MEDI4920 300 mg
Biological: MEDI4920 1000 mg
Other: Placebo
Biological: MEDI4920 100 mg
Biological: MEDI4920 30 mg
Biological: MEDI4920 3000 mg

First Posted Date: 2014-05-30

Last Posted Date: 2019-02-15

Lead Sponsor: MedImmune LLC

Target Recruit Count: 59

Registration Number: NCT02151110

Locations: 🇬🇧
Research Site, Leeds, United Kingdom

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Phase 1

Completed

Conditions: Clear Cell Renal Cell Carcinoma
Select Advanced Malignancies
Kidney Cancer

Interventions: Biological: MEDI0680
Biological: Nivolumab
Biological: Durvalumab

First Posted Date: 2014-04-21

Last Posted Date: 2021-06-01

Lead Sponsor: MedImmune LLC

Target Recruit Count: 97

Registration Number: NCT02118337

Locations: 🇬🇧
Research Site, Southampton, United Kingdom

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Biological: MEDI4736 Evaluate MEDI4736 in MDS
Biological: tremelimumab
Drug: VIDAZA

First Posted Date: 2014-04-17

Last Posted Date: 2019-05-10

Lead Sponsor: MedImmune LLC

Target Recruit Count: 67

Registration Number: NCT02117219

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

Phase 1

Completed

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Biological: MEDI7510 (20 mcg RSV sF)
Biological: RSV sF 50 mcg
Biological: Placebo
Biological: RSV sF 80 mcg
Biological: RSV sF 20 mcg
Biological: MEDI7510 (50 mcg RSV sF)
Biological: MEDI7510 (80 mcg RSV sF)

First Posted Date: 2014-04-16

Last Posted Date: 2016-10-21

Lead Sponsor: MedImmune LLC

Target Recruit Count: 246

Registration Number: NCT02115815

Locations: 🇺🇸
Accelovance, Inc, Rockville, Maryland, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸
Compass Research, Orlando, Florida, United States

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: MEDI8897 Intravenous
Drug: MEDI8897 Intramuscular
Drug: Placebo

First Posted Date: 2014-04-15

Last Posted Date: 2016-11-28

Lead Sponsor: MedImmune LLC

Target Recruit Count: 342

Registration Number: NCT02114268

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Gefitinib
Drug: MEDI4736

First Posted Date: 2014-03-14

Last Posted Date: 2022-04-04

Lead Sponsor: MedImmune LLC

Target Recruit Count: 56

Registration Number: NCT02088112

Locations: 🇰🇷
Research Site, Seoul, Korea, Republic of

A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Subjects or Volunteers
Asthma

Interventions: Biological: Tralokinumab 300 mg

First Posted Date: 2014-03-12

Last Posted Date: 2018-12-31

Lead Sponsor: MedImmune LLC

Target Recruit Count: 60

Registration Number: NCT02085473

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States
🇺🇸
Research Site, Lincoln, Nebraska, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy